Market Performance
Chemomab Therapeutics (CMMB) closed down 2.54 % on Friday, 23 November 2026, at 05:29 AM Central Europe.
- Current trading price: USD 1.08
- Shares outstanding: 7.3 million
- Market capitalisation: USD 8.4 million
- Volume traded in the last 24 hours: USD 17 000
- 200‑day simple moving average: USD 1.78
- 52‑week high: USD 3.44 (27 October 2025)
- 52‑week low: USD 1.05 (30 September 2026)
- Month‑end performance: down 51.68 % since 30 October 2026
Related Stock Movements – Last 24 Hours
| Company | Ticker | % Change | Current Price | Market Capitalisation |
|---|---|---|---|---|
| Collplant Biotechnologies Ltd | CLGN | –3.22 % | USD 3.62 | USD 7.1 million |
| Nutritional Growth | NGS.AX | 0 % | AUD 0.02 | AUD 9.8 million |
| Rail Vision | RVSN | +15.83 % | USD 3.12 | USD 6.6 million |
| Land Development Nimrodi Gro | ILDC.TA | 0 % | ILA 3,940 | ILA 521.3 million |
| Aryt Industries | ARYT.TA | –2.11 % | ILA 1,515 | ILA 520 million |
Price‑to‑earnings ratios
- Land Development Nimrodi Gro: 6.47
- Aryt Industries: 5.56
Company Overview
Chemomab Therapeutics Ltd. is a clinical‑stage biopharmaceutical company that focuses on discovering and developing therapies for fibrosis‑related diseases. The company operates globally, with its headquarters in Tel Aviv, Israel. Chemomab Therapeutics is listed on the Nasdaq stock exchange and conducted its initial public offering on 12 February 2019. The company’s official website is www.chemomab.com .
